Antibiotics Tied to Lower Effectiveness of Childhood Vaccines

Use of the drugs in children under the age of two was associated with lower antibody levels after the jabs—perhaps, researchers suggest, due to microbiome alterations.

Written byNatalia Mesa, PhD
| 2 min read
Baby face up in spotted onesie about to get an injection with a vaccine
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

A study published yesterday (April 27) in Pediatrics finds that children who received a course of antibiotics during the first two years of life had diminished immune responses to four common vaccines. Researchers tell Science News that the findings are a cautionary tale about overusing antibiotics.

Babies are typically immunized against various diseases in the first six months of life and get boosters in their second year. From 2000 to 2016, the study’s authors collected blood samples from 560 children ages 6 to 24 months during routine visits with their pediatricians, measuring antibody levels after the children received polio, diphtheria-tetanus-pertussis, Haemophilus influenzae type b, and pneumococcal vaccines.

Of these children, 342 had collectively been prescribed close to 1,700 courses of antibiotics. The other 218 children had not received antibiotics. The team analyzed whether antibody levels induced by the four vaccines met the threshold of what is considered protective and found ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • A black and white headshot

    As she was completing her graduate thesis on the neuroscience of vision, Natalia found that she loved to talk to other people about how science impacts them. This passion led Natalia to take up writing and science communication, and she has contributed to outlets including Scientific American and the Broad Institute. Natalia completed her PhD in neuroscience at the University of Washington and graduated from Cornell University with a bachelor’s degree in biological sciences. She was previously an intern at The Scientist, and currently freelances from her home in Seattle. 

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies